48,830
edits
Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
SMARCA4-deficient non-small cell carcinoma of the lung (view source)
Revision as of 15:57, 31 October 2023
, 15:57, 31 October 2023no edit summary
| Line 12: | Line 12: | ||
*HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | *HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | ||
*SMARCA4 -ve. | *SMARCA4 -ve. | ||
*Napsin A -ve (1/28 +ve).<ref>{{cite journal |authors=Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. |title=34th European Congress of Pathology - Abstracts ( | *Napsin A -ve (1/28 +ve).<ref>{{cite journal |authors=Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. |title=34th European Congress of Pathology - Abstracts (''Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status'') |journal=Virchows Arch |volume=481 |issue=Suppl 1 |pages=1–364 |date=August 2022 |pmid=35972647 |pmc=9379246 |doi=10.1007/s00428-022-03379-4 |url=}}</ref> | ||
Note: | Note: | ||